Koninklijke Philips (PHIA) Q2 2025 earnings summary

Executive summary

• Q2 2025 saw 6% order intake growth and 1% sales growth, led by Personal Health, while Diagnosis & Treatment and Connected Care declined slightly.

• Adjusted EBITA/EBITDA margin expanded by 130 bps to 12.4%, driven by innovation, productivity, and product mix.

• Free cash flow increased to EUR 230 million, reflecting disciplined working capital management and lower Respironics-related payments.

• Full-year 2025 outlook for comparable sales growth reiterated at 1%-3%, with raised adjusted EBITA/EBITDA margin and free cash flow guidance.

• Major AI-powered product launches and a multi-year partnership with Indonesia's Ministry of Health expanded access to advanced therapies.

Financial highlights

• Q2 2025 sales: EUR 4,338 million, up 1% year-over-year; income from operations: EUR 400 million.

• Adjusted EBITA: EUR 540 million (12.4% margin), up 130 bps year-over-year.

• Free cash flow: EUR 230 million, a year-on-year improvement of EUR 294 million.

• Adjusted diluted EPS from continued operations: EUR 0.36, up 20% year-over-year.

• Gross margin strengthened by innovation and productivity, partially offset by cost inflation and currency headwinds.

Outlook and guidance

• Full-year comparable sales growth outlook maintained at 1%-3%, with sequential improvement expected and stronger weighting in Q4.

• Adjusted EBITA/EBITDA margin guidance raised to 11.3%-11.8%, up 50 bps, factoring in EUR 150-200 million tariff impact.

• Free cash flow guidance for 2025 increased to EUR 0.2-0.4 billion, including Respironics settlement payout.

• Outlook excludes ongoing Respironics-related proceedings and DOJ investigation.

• Q3 adjusted EBITDA margin expected to decline year-over-year due to tariff timing and royalty income phasing.